Current and future status of JAK inhibitors

• Published in: The Lancet (British edition) Vol. 398; no. 10302; pp. 803 - 816
• Main Authors: McLornan, Donal P, Pope, Janet E, Gotlib, Jason, Harrison, Claire N
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 28.08.2021; Elsevier Limited
• Subjects: Arthritis; Arthritis, Rheumatoid - drug therapy; Cytokines; Drug dosages; FDA approval; Gene amplification; Hematology; Humans; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Inhibitors; Janus kinase; Janus Kinase Inhibitors - therapeutic use; Kinases; Lymphoma; Mutation; Myeloproliferative Disorders - drug therapy; Neoplasms; Nitriles - therapeutic use; Oncology; Phlebotomy; Piperidines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - therapeutic use; Pyrimidines - therapeutic use; Pyrrolidines - therapeutic use; Rheumatoid arthritis; Signal transduction; Signal Transduction - drug effects; Sulfonamides - therapeutic use; Transcription; Tumors; New York; United States > US
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(21)00438-4

An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease states has led to an increasing applicability of therapeutic intervention with JAK inhibitors. These agents have revolutionised treatments for a heterogeneous group of disorders, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease, and multiple immune-driven dermatological diseases, exemplifying rapid bench-to-bedside translation. In this Therapeutics paper, we summarise the currently available data concerning the successes and safety of an array of JAK inhibitors and hypothesise on how these fields could develop.